Hemp lotion absorption under the microscope: new study launches
NCT ID NCT07603518
First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 4 times
Summary
This early-stage study will test how a hemp-based CBD lotion with a small amount of THC is absorbed by the body. Twenty healthy adults will use the lotion in a clean, controlled environment. Researchers will measure cannabinoid levels in saliva, blood, and urine over time to understand how the body processes these compounds when applied to the skin.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- hemp-based CBD topical lotion with low THC
- What this could lead to
- If successful, this study could help understand how topical cannabinoids enter the body, guiding future research on their effects.
- What could go wrong
- This is a very early Phase 1 study with only 20 participants, so results may not apply to the general population. It measures absorption, not health benefits or risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2026
- Expected to finish
-
Sep 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Have provided written informed consent * Be between the ages of 18 and 55 * Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests * Test negative for recent cannabis use in urine at the screening visit and again upon admission for the inpatient stay. * Test negative for other drugs of abuse, including alcohol, at the screening visit and again upon admission for the inpatient stay. * Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at each study visit. * Have a body mass index (BMI) in the range of 18 to 38 kg/m2 * Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg * Report prior experience using cannabis or CBD products. Exclusion Criteria: * Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine in the month prior to the screening visit. * History of or current evidence of significant medical or psychiatric illness judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures. * Current use of medications which, in the opinion of the investigator or medical monitor, will interfere with the study results or the safety of the subject. * History of xerostomia (dry mouth), or the presence of mucositis, gum infection or bleeding, or other significant oral cavity disease or disorder that in the investigator's opinion may affect the collection of oral fluid samples. * Known allergy to any ingredients in the study drug. * Enrolled in another clinical trial or have received any drug as part of a research study within 30 days prior to dosing.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cannabis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Behavioral Pharmacology Research Unit
RECRUITINGBaltimore, Maryland, 21224, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which cannabis warnings stick? study puts messages to the test
- Cannabis compounds may rewire memory retrieval, brain scans suggest
- Hemp seed allergy risk under the microscope: new study launches
- Teens see vape labels: will warnings work?
- Cannabis study probes memory and brain activity in regular users
- Study reveals how booze and weed mess with your driving